

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country.

Statement of Discontinuation of the study	
Name of Company: GlaxoSmithKline Biologicals	
Study No: 200255 (EudraCT# 2014-000060-17)	
Product: SB580299	
Title: A phase IIIb, open-label, non-randomised, multicentre study to assess the immunogenicity and safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine when administered intramuscularly according to a 2-dose schedule in healthy female adolescents or intramuscularly according to a 3-dose schedule in healthy female adults, 6.5 years after first vaccine dose in study HPV-048 PRI (110659).	
Phase: IIIb	
Study Period: January 2015 to April 2015	
Centres: NA	
Number of Subjects: 0	
Publications: NA	
Statement on discontinuation of the study: Discontinued by GlaxoSmithKline during preparation of the trial. No patient entered the study, therefore no results / data are available.	